Labcorp Holdings vs ResMed

Labcorp Holdings (LH), health care, and ResMed (RMD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

ResMed is worth $33.5B on the stock market and Labcorp Holdings $29.9B: ResMed is valued at 12% more. Labcorp Holdings trades at 30.2 times earnings and ResMed at 21.7; operating margins in their latest fiscal years were 9.92% and 33.4%. Over the past year Labcorp Holdings's share price has moved +43.4% and ResMed's -3.26%.

Key facts

Labcorp Holdings market value
$29.9B
ResMed market value
$33.5B
Labcorp Holdings P/E
30.2
ResMed P/E
21.7
Labcorp Holdings revenue
$14BFY to 2025-12-31
ResMed revenue
$5.7BFY to 2026-06-30
Superinvestors holding both
0

Market values as of .

Labcorp Holdings vs ResMed: every measure side by side
Measure Labcorp Holdings ResMed
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312026-06-30
Size
Market cap$29.9Blower$33.5Bhigher
Revenue$14Bhigher$5.7Blower
Earnings$876.5Mlower$1.5Bhigher
Employees71,000higher11,370lower
Total assets$18.4Bhigher$9Blower
Valuation
P/E30.2higher21.7lower
P/S2.1lower5.9higher
P/B3.4lower5.6higher
Dividend yield0.77%lower1.03%higher
Profitability
Operating margin9.92%lower33.4%higher
Balance sheet
Net assets$8.6Bhigher$6.6Blower
Total liabilities$9.8Bhigher$2.4Blower
Total debt$5.6Bhigher$659.4Mlower
Cash on hand$532.3Mlower$1.5Bhigher
Price change
Today-1.13%lower-0.14%higher
1 year+43.4%higher-3.26%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

ResMed only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns LH · Who owns RMD

Further comparisons

Learn

Questions and answers

Which is bigger, Labcorp Holdings or ResMed?

By market value, ResMed is the larger: $33.5B against $29.9B for Labcorp Holdings. By revenue in its latest fiscal year, Labcorp Holdings is the larger: $14B against $5.7B for ResMed.

Which has the higher P/E ratio?

Labcorp Holdings: 30.2, against 21.7 for ResMed. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

ResMed: 33.4%, against 9.92% for Labcorp Holdings. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

ResMed: 1.03%, against 0.77% for Labcorp Holdings. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Labcorp Holdings: $5.6B, against $659.4M for ResMed. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Labcorp Holdings and ResMed?

None of the tracked superinvestors holds both in their latest 13F filing. 7 hold Labcorp Holdings and 1 holds ResMed.

Cite this page

Funkfolio, “Labcorp Holdings vs ResMed”, data as of 18 November 2026. https://funkfolio.com/compare/lh-vs-rmd

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.